Synaptogenix Inc (SNPX)

[XenaLives]

Geez, we aren't talking about competing hamburger stands here.

The science will call the winners and losers.

IMO Anavex will make more money by targeting a broad based CNS disease market with 2-73. NTRP's Bryostatin may be helpful to some, but many potential customers simply won't need the drug because 2-73 will prevent, slow, and reverse cognitive decline.